Finally, we assessed the inhibition effect of the AURKA PROTAC cocktail in malignant bone marrow mononuclear cells (BMMCs) obtained by gradient centrifuged from three pathologically confirmed de novo AML patients. The gene discussed is AURKA; the disease is acute myeloid leukemia.